The oral delivery of BCS III and BCS IV small molecules has two key challenges: solubility and permeability. ProPerma uniquely improves both permeability and bioavailability of BCS III and BCS IV small molecules by deploying an innovative and bespoke combination of GRAS and novel enhancing excipients. Our “formulation toolbox” of excipients falls within the pharmaceutically accepted domain.
Unlike other technologies, ProPerma improves both permeability and bioavailability by deploying a smart combination of pH-lowering, membrane wetting, charge dispersal and solubilizing agents without making physicochemical modifications to the partner’s API.
Enteris has demonstrated positive results in several clinical studies, including pivotal Phase 3 trials. As a true full-service partner of choice, Enteris BioPharma is uniquely qualified to provide integrated support from the earliest stages of research through late stage clinical trials.
ProPerma Mechanism of Delivery in Four Key Steps
Enteris’s ProPerma oral formulation technology is made up of two key components, the first is a permeation enhancer, which loosens tight junctions in the intestinal enterocytes and allows paracellular transport. The permeation enhancer, a surfactant, also acts as a great solubilizing agent. The other main excipient, citric acid, also plays an active, multifunctional role in transport by acting as a calcium chelator and membrane permeation enhancer, a pH-lowering agent that increases absorptive flux, and a membrane wetting/charge dispersal agent.
Enteris has demonstrated its ability to effectively deliver a variety of molecules across multiple therapeutic indications.